𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

✍ Scribed by Steven A Narod; Jean-Sébastien Brunet; Parviz Ghadirian; Mark Robson; Ketil Heimdal; Susan L Neuhausen; Dominique Stoppa-Lyonnet; Caryn Lerman; Barbara Pasini; Patricia de los Rios; Barbara Weber; Henry Lynch

Book ID
117276245
Publisher
The Lancet
Year
2000
Tongue
English
Weight
98 KB
Volume
356
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tamoxifen and contralateral breast cance
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
✍ Jacek Gronwald; Nadine Tung; William D. Foulkes; Kenneth Offit; Ruth Gershoni; M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB

## Abstract Women with a mutation in __BRCA1__ or __BRCA2__ face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the10‐year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is